All In Biotech

Drug Trial Radar · NCT03940352

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

52

Actual

Start

Jun 24, 2019

Primary completion

Aug 20, 2024

Study completion Aug 20, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS. For all subjects, TP53wt status had to be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8. Two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and HDM201+venetoclax (treatment arm 2). * In the treatment arm 1, subjects received HDM201 in combination with MBG453. * In the treatment arm 2, subjects received HDM201 in combination with venetoclax. Venetoclax dose was gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that was subsequently continued. Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with MBG453 or venetoclax in AML and high-risk MDS subjects was planned to be determined for each treatment arm.

Conditions

  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)

Interventions

  • HDM201Drug

    Capsule

  • MBG453Biological

    LIVI (Liquid in vial) Concentrate for Solution for infusion

  • VenetoclaxDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: at month 24
  2. Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: at month 24
  3. Incidence of dose limiting toxicities (DLTs) of treatmentTime frame: at day 28
  4. Frequency of dose interuptionsTime frame: at month 24
  5. Frequency of dose reductionsTime frame: at month 24
  6. Dose intensitiesTime frame: at month 24

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Duke University Medical Center .

    Durham, North Carolina

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.